Biovail Corporation volatility and risk adjusted return

Biovail (BVF) and Acadia Pharmaceuticals (ACAD) are moving forward with a 3-pronged strategy for pimavanserin. Acadia plans a phase III trial in Parkinson's disease psychosis (PDP) and a phase II feasibility study in Alzheimer's disease ...

Biovail (NYSE: BVF) closed yesterday at $15.09. So far the stock has hit a 52-week low of $9.26 and 52-week high of $16.14. Biovail stock has been showing support around 14.86 and resistance in the 15.42 range. ...

Plot Summary: A comedy about a veteran NYPD cop whose rare baseball card is stolen. Since it's his only hope to pay for his daughter's upcoming wedding, he recruits his partner to track down the thief, a memorabilia-obsessed gangster. ...

The Worse the Stock, The Better the Return: Canadian Edition (at Seeking Alpha)

We believe Acadia represents an attractive acquisition target for Biovail should pimavanserin offer positive data in any one of the three indications.